metaPreg - Methotrexate (Post-conception) during pregnancy

Methotrexate (Post-conception)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	3.16 [1.52, 6.54]	0%	5 studies	32,664	143	not evaluable	ROB	5.76 [2.42; .]
Major congenital malformations	2.70 [1.21, 6.02]	0%	4 studies	32,664	143	not evaluable	ROB	4.85 [1.72; .]
Congenital heart defects	4.80 [0.57, 40.39]	37%	2 studies	11,023	30	not evaluable	ROB	-
6 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
2 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Late intrauterine deaths (> 22 weeks)	5.05 [1.21, 21.03]	0%	2 studies	9	211	not evaluable	ROB	9.58 [1.73; .]
Early intrauterine death (< 22 weeks)	2.50 [1.43, 4.38]	-	1 study	118	188	not evaluable	ROB	4.44 [2.21; .]
Elective/induced termination of pregnancy	7.40 [4.49, 12.18]	-	1 study	98	188	not evaluable	ROB	14.28 [8.46; .]
Therapeutic terminations of pregnancy	4.23 [1.78, 10.04]	-	1 study	22	188	not evaluable	ROB	7.93 [2.96; .]
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value